U.S., May 23 -- ClinicalTrials.gov registry received information related to the study (NCT07604792) titled 'FIT-(BCMA+CD19)-CAR-T Cells in Recurrent/Refractory Autoimmune Diseases Patients.' on May 17.
Brief Summary: This study is a single-center, open-label, single-dose exploration clinical trial for treating patients with partially relapsed/refractory autoimmune diseases by infusing FIT-(BCMA+CD19)-CAR-T cells after pre-treatment with cleansing therapy.
In this study phase, a traditional "3+3" trial design is employed for dose escalation.
Study Start Date: Sept. 25, 2025
Study Type: INTERVENTIONAL
Condition:
Autoimmune Diseases
Intervention:
BIOLOGICAL: FIT-(BCMA+CD19)-CAR-T Cells
Before cell infusion, researchers may decide, bas...